Holen Sie sich die Stockscreener-App
34.52
3.17%
1.06
Schlusskurs vom Vortag:
$33.46
Offen:
$33.77
24-Stunden-Volumen:
1.14M
Relative Volume:
3.73
Marktkapitalisierung:
$619.20M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-246.57
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
+42.41%
1M Leistung:
+82.84%
6M Leistung:
+65.80%
1J Leistung:
+206.84%
1-Tages-Spanne:
$33.30
$35.17
1-Wochen-Bereich:
$26.00
$35.17
52-Wochen-Spanne:
$11.22
$35.17
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
34.52 | 600.18M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT - Insider Monkey
RIPK1 Inhibitor Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape - The Globe and Mail
Best Momentum Stock to Buy for August 8th - MSN
Rigel targets up to $280M 2025 revenue as IRA boosts sales and pipeline advances - MSN
Is Rigel Pharmaceuticals Inc. a candidate for recovery playPredictable Entry Strategy With Technical Backing - Newser
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy? - Yahoo Finance
Top 5 Stocks with Strong Price Performance to Buy Now - AInvest
5 Best Stocks With Relative Price Strength to Buy Right Now - sg.finance.yahoo.com
Results: Rigel Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
New Strong Buy Stocks for August 8th - TradingView
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2025 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals Flips To A Profit On Rising Sales - Finimize
Rigel (RIGL) Gets a Buy from Citi - The Globe and Mail
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Citi Analysts Maintain Buy Rating on Rigel with $67 Price Target - AInvest
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates - MSN
Rigel Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $67 - 富途牛牛
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (NASDAQ:RIGL) Shareholder Returns Have Been Solid, Earning 160% in 1 Year - 富途牛牛
Cantor Fitzgerald Raises Price Target for RIGL to $32.00, Mainta - GuruFocus
Rigel Pharmaceuticals shares surge 16.67% intraday after strong Q2 earnings and revenue guidance. - AInvest
Rigel Pharmaceuticals: Cantor Fitzgerald Maintains Neutral, PT Raised to $32 from $23. - AInvest
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28% - simplywall.st
Rigel (RIGL) Q2 Revenue Jumps 176% - The Globe and Mail
Rigel (RIGL) Q2 Revenue Jumps 176% - The Motley Fool
Jefferies raises Rigel Pharmaceuticals stock price target on strong sales By Investing.com - Investing.com Nigeria
Jefferies raises Rigel Pharmaceuticals stock price target on strong sales - Investing.com
RIGL files S-8 to register 825,000 shares for employee equity plans | RIGL SEC FilingForm S-8 - Stock Titan
Rigel Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Rigel: Q2 Earnings Snapshot - New Haven Register
Rigel Pharmaceuticals Exceeds Q2 2025 Revenue Guidance with 76% YoY Increase - AInvest
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlight - GuruFocus
Rigel Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Rigel Pharmaceuticals' Q2 2025: Unpacking Contradictions in Tavalisse Growth and GAVRETO Sales Dynamics - AInvest
Rigel Pharmaceuticals Sets Ambitious 2025 Revenue Target of $280M as IRA Boosts Sales and Pipeline Advances - AInvest
Rigel Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL): A High-Growth Biotech Play with a Self-Funding Pipeline and Expanding Global Reach - AInvest
Transcript : Rigel Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: Rigel Pharmaceuticals Q2 2025 boosts guidance, stock rises - Investing.com India
Earnings call transcript: Rigel Pharmaceuticals Q2 2025 boosts guidance, stock rises By Investing.com - Investing.com South Africa
RIGL Updates FY25 Revenue and Sales Projections - GuruFocus
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rigel Pharmaceuticals' Q2 Earnings Momentum and Analyst Optimism: Assessing the Sustainability of Outperformance for Long-Term Investors - AInvest
Rigel Pharmaceuticals Q2 revenue beats estimates - MarketScreener
Rigel Pharmaceuticals reports Q2 EPS $3.91, consensus $1.40 - TipRanks
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Sanofi, Genfleet Therapeutics, Rigel Pharma, GlaxoSmithKline, AbbVie, Sanofi - The Globe and Mail
Silvercorp Announces Ecuador Constitutional Court Decision Upholding Environmental License for El Domo Project - The Globe and Mail
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):